The aim of this study was to validate, in an independent larger series of 89 patients, the prognostic value of KRAS mutations on response to cetuximab and survival.

• 本研究目的是为了确认：在一个独立的更多的89个患者中，KRAS突变对于西妥昔单抗的反应与生存的预测价值。